Nanion Technologies and Nexel Partner to Open a New Reference Demonstration Laboratory in South Korea

Nanion Technologies and Nexel are pleased to announce a partnership, focused on combining Nanion’s CardioExcyte 96 and FLEXcyte 96 cell monitoring technology with Nexel’s hiPSC-derived cells for demonstration purposes. Bringing together the two companies’ infrastructure and expertise serves to meet the growing demand for a reliable, high throughput cell monitoring technology in Asia.

The Nanion- Nexel partnership brings together profound skills in comprehensive in vitro electrophysiology technology and development of human induced pluripotent stem cells (hiPSCs), with focus on cardiomyocytes. Under the partnership, Nexel opens a reference demonstration laboratory for Nanion´s systems at Nexel’s headquarters in Seoul, whereby both companies aim to significantly upscale support of their clients in Asia.

Dr Choong-Seong Han, CEO of Nexel, said: “Nexel is proud to start this partnership with Nanion Technologies. We believe it will further build on the excellent relationship we have developed together in the last year. The Cardiosight®-S cardiomyocytes have been fully validated on the CardioExcyte 96 and FLEXcyte 96 systems and our expert scientists are dedicated to provide the best demo settings as well as product experience for customers, as part of the collaboration. We hope interest in both Nanion’s and Nexel’s offerings will increase with our collaborative efforts.”

Frank Henrichsen, Director of Global Sales of Nanion Technologies added: “We are very eager to strengthen our position in the Asian market and especially in Korea. In Nexel, we see a valuable partner to help us develop our presence, in this case through opening their laboratories and enabling the use Nanion´s technology for demo purposes at their premises. Combining Nexel´s hiPSC-derived cardiomyocytes and cardiac in vitro assays with Nanion’s CardioExcyte 96 and FLEXcyte 96 systems, we are confident that our customers will get an excellent package solution for use in safety pharmacology and toxicology assays. We are also very happy that Nexel has already implemented the systems into their quality control procedure of  Cardiosight®-S cardiomyocytes.”